{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:56:37Z","timestamp":1765382197054,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jval.2019.08.012","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T18:26:48Z","timestamp":1571941608000},"page":"180-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Na\u00efve Patients With Chronic Hepatitis C Virus"],"prefix":"10.1016","volume":"23","author":[{"given":"Christopher G.","family":"Fawsitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham S.","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Brainard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham S.","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Gore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Guha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Halford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Whitby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Howe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Irving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Khakoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Klenerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Massetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamyo","family":"Mbisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"McHutchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"McKeating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"McLauchlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alec","family":"Miners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Zitzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicky J.","family":"Welton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2017","series-title":"Global Hepatitis Report 2017","key":"10.1016\/j.jval.2019.08.012_bib1"},{"year":"2016","series-title":"Global Health Sector Strategy on Viral Hepatitis 2016-2021","key":"10.1016\/j.jval.2019.08.012_bib2"},{"issue":"9","key":"10.1016\/j.jval.2019.08.012_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"year":"2015","series-title":"Technology Appraisal Guidance [TA363]: Ledipasvir\u2013Sofosbuvir for Treating Chronic Hepatitis C","key":"10.1016\/j.jval.2019.08.012_bib4"},{"issue":"3","key":"10.1016\/j.jval.2019.08.012_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"year":"2016","series-title":"Technology Appraisal Guidance [TA413]: Elbasvir\u2013Grazoprevir for Treating Chronic Hepatitis C","key":"10.1016\/j.jval.2019.08.012_bib6"},{"issue":"3","key":"10.1016\/j.jval.2019.08.012_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/apt.13882","article-title":"The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naive and treatment-experienced) subjects treated with all-oral elbasvir\/grazoprevir regimens in the United States","volume":"45","author":"Elbasha","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jval.2019.08.012_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/CEOR.S117650","article-title":"Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service","volume":"9","author":"Westerhout","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.jval.2019.08.012_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1306227","article-title":"Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1","volume":"370","author":"Kowdley","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jval.2019.08.012_bib10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jval.2018.12.011","article-title":"A\u00a0cost-effectiveness analysis of shortened direct-acting antiviral treatment in genotype 1 non-cirrhotic treatment-na\u00efve patients with chronic hepatitis C virus","volume":"22","author":"Fawsitt","year":"2019","journal-title":"Value Health"},{"year":"2018","series-title":"Technology Appraisal Guidance [TA499]: Glecaprevir\u2013Pibrentasvir for Treating Chronic Hepatitis\u00a0C","key":"10.1016\/j.jval.2019.08.012_bib11"},{"year":"2013","series-title":"Guide to the Methods of Technology Appraisal 2013","key":"10.1016\/j.jval.2019.08.012_bib12"},{"issue":"17","key":"10.1016\/j.jval.2019.08.012_bib13","doi-asserted-by":"crossref","first-page":"i","DOI":"10.3310\/hta15170","article-title":"Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV\/HIV co-infection: a systematic review and economic evaluation","volume":"15","author":"Hartwell","year":"2011","journal-title":"Health Technol Assess"},{"issue":"22","key":"10.1016\/j.jval.2019.08.012_bib14","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jval.2019.08.012_bib15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/gut.2005.064774","article-title":"Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C","volume":"55","author":"Grieve","year":"2006","journal-title":"Gut"},{"issue":"21","key":"10.1016\/j.jval.2019.08.012_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10210","article-title":"Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation","volume":"10","author":"Wright","year":"2006","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1016\/j.jval.2019.08.012_bib17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jval.2019.08.012_bib18","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon\u00a0and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"Cardoso","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.jval.2019.08.012_bib19","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/0003-4819-127-10-199711150-00001","article-title":"Estimates of the cost-effective of a single course of interferon-alpha2b in patients with histologically mild chronic hepatitis C","volume":"127","author":"Bennett","year":"1997","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.jval.2019.08.012_bib20","first-page":"983","article-title":"Economic evaluation of ombitasvir\/paritaprevir\/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection","volume":"19","author":"Johnson","year":"2016","journal-title":"J\u00a0Med Econ"},{"year":"2018","series-title":"Technology Appraisal Guidance [TA507]: Sofosbuvir\u2013Velpatasvir\u2013Voxilaprevir for Treating Chronic Hepatitis C","key":"10.1016\/j.jval.2019.08.012_bib21"},{"issue":"3","key":"10.1016\/j.jval.2019.08.012_bib22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/jvh.12132","article-title":"The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy","volume":"21","author":"Backx","year":"2014","journal-title":"J\u00a0Viral Hepatol"},{"issue":"1","key":"10.1016\/j.jval.2019.08.012_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamainternmed.2015.6011","article-title":"Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population","volume":"176","author":"Chahal","year":"2016","journal-title":"JAMA Intern Med"},{"year":"2018","series-title":"National Clinical Guidelines for the Treatment of HCV in Adults","key":"10.1016\/j.jval.2019.08.012_bib24"},{"year":"2018","series-title":"Specialised Commissioning Drugs Briefing: Spring 2018","key":"10.1016\/j.jval.2019.08.012_bib25"},{"issue":"10","key":"10.1016\/j.jval.2019.08.012_bib26","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/MEG.0000000000001192","article-title":"Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study","volume":"30","author":"Solund","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"year":"2017","series-title":"Unit Costs of Health and Social Care 2017","author":"Curtis","key":"10.1016\/j.jval.2019.08.012_bib28"},{"year":"2017","series-title":"Technology Appraisal Guidance [TA507]: Sofosbuvir\u2013Velpatasvir for Treating Chronic Hepatitis\u00a0C","key":"10.1016\/j.jval.2019.08.012_bib29"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301519351307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301519351307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:18:09Z","timestamp":1761095889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301519351307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1098301519351307"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2019.08.012","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Na\u00efve Patients With Chronic Hepatitis C Virus","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2019.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}